DNMT3A and myeloid neoplasm: The most frequent mutation, DNMT3A R882, disrupts the enzyme’s ability to effectively methylate DNA, leading to the development and progression of myeloid malignancies by affecting the expression of genes involved in cell differentiation and proliferation [9, 10].